Regional Differences in Serotonin Transporter Occupancy by Escitalopram: An [11C]DASB PK-PD Study
- 24 August 2016
- journal article
- research article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 56 (4) , 371-381
Abstract
Background and objective Escitalopram is one of the most commonly prescribed selective serotonin reuptake inhibitors (SSRIs). It is thought to act by blocking the serotonin transporter (SERT). However, its dose–SERT occupancy relationship is not well known, so it is not clear what level of SERT blockade is achieved by currently approved doses. Methods To determine the dose–occupancy relationship, we measured serial SERT occupancy using [11C]DASB [3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile] positron emission tomography (PET) and plasma drug concentrations after the administration of escitalopram in 12 healthy volunteers. We then built a pharmacokinetic–pharmacodynamic model to characterize the dose–occupancy relationship in the putamen and the dorsal raphe nucleus. Results Escitalopram at approved doses occupied less SERT than expected and the SERT occupancy showed regional effects [occupancy was higher in the dorsal raphe nucleus than in the putamen (p < 0.001)]. The drug concentration when 50 % of receptors are occupied (EC50) value and Hill coefficient were significantly different between the putamen (EC50 4.30, Hill coefficient 0.459) and the dorsal raphe nucleus (EC50 2.89, Hill coefficient 0.817). Conclusions Higher doses of escitalopram than 20 mg are needed to achieve 80 % or greater SERT occupancy. Higher occupancy by escitalopram in the dorsal raphe nucleus relative to the striatum may explain the delayed onset of action of SSRIs by modulating autoreceptor function. The prevention of the 5-HT1A autoreceptor-mediated negative feedback could be a strategy for accelerating the clinical antidepressant effects.Keywords
Funding Information
- National Research Foundation of Korea (NRF-2015R1A5A7037676)
- SNUBH Research Fund (14-2014-007)
This publication has 46 references indexed in Scilit:
- Escitalopram tolerability as mono- versus augmentative therapy in patients with affective disorders: a naturalistic studyNeuropsychiatric Disease and Treatment, 2013
- Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge studyMolecular Psychiatry, 2012
- Predicting Brain Occupancy from Plasma Levels using PET: Superiority of Combining Pharmacokinetics with Pharmacodynamics while Modeling the RelationshipJournal of Cerebral Blood Flow & Metabolism, 2011
- What is the optimal dose of escitalopram for the treatment of obsessive–compulsive disorder? A naturalistic open-label studyInternational Clinical Psychopharmacology, 2011
- Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot studyBMC Psychiatry, 2011
- Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysisThe Lancet, 2009
- Estimates of Serotonin and Norepinephrine Transporter Inhibition in Depressed Patients Treated with Paroxetine or VenlafaxineNeuropsychopharmacology, 2008
- High‐dose escitalopram in the treatment of binge‐eating disorder with obesity: a placebo‐controlled monotherapy trialHuman Psychopharmacology: Clinical and Experimental, 2007
- Escitalopram Therapy for Major Depression and Anxiety DisordersAnnals of Pharmacotherapy, 2007
- Serotonin Transporter Occupancy of Five Selective Serotonin Reuptake Inhibitors at Different Doses: An [11C]DASB Positron Emission Tomography StudyAmerican Journal of Psychiatry, 2004